Re-engineering patients’ immune cells to treat their cancers is a rapidly growing field in cancer treatment. One of the world’s newest forms of cancer immunotherapies, CAR-T cell therapy, has generated enormous global excitement due to promising results in treating some blood cancers. The joint project will develop a new cellular nanotechnology that is urgently needed to sidestep viral-based CAR-T manufacturing and therapy, by using recently developed and novel programmable nanoneedles – powerful arrays of vertical high-aspect-ratio nanostructures.